The Magazine for Sleep Professionals
Friday, April 3, 2026
Sunrise announces its partnership with Prevent Dementia. This collaboration brings together research on mild-life risk factors for Alzheimer’s Disease with Sunrise’s advanced sleep monitoring expertise, opening new avenues in dementia research. The PREVENT Dementia Research Programme aspires to enhance the ability to predict individuals at the highest risk of developing […]
Fisher & Paykel Healthcare Corporation Limited has announced the launch of the F&P Solo™ Nasal mask in the USA for the treatment of obstructive sleep apnea (OSA). The world’s first AutoFit™ mask, F&P Solo, simplifies setup like no other, enabling users to stretch the mask onto the face and adjust […]
Centessa Pharmaceuticals plc announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug application (IND) to initiate a Phase 1 first-in-human clinical trial of ORX750 for the treatment of narcolepsy. ORX750 is an investigational, orally administered, highly potent and selective orexin receptor 2 (OX2R) agonist […]
Nox Medical, the medical device business unit of Nox Health, announced its receipt of patents from the United States Patent and Trademark Office (USPTO) and the European Patent Office (EPO) related to the Nox RIP [respiratory inductance plethysmography] belts, which are incorporated into all of Nox Medical’s diagnostic sleep tests. […]
Nyxoah SA today announced the appointment of Dr. Maurits S. Boon, MD as Chief Medical Officer. Dr. Boon joins Nyxoah from Thomas Jefferson University, where he will continue part-time as a professor and Vice Chairman, Education. He is dual board-certified in otolaryngology – head and neck surgery, as well as […]
Harmony Biosciences Holdings, Inc. has announced an exclusive licensing agreement with Bioprojet to develop, manufacture and commercialize TPM-1116, a highly potent and selective oral orexin-2 receptor (OX2R) agonist that will be evaluated for the treatment of narcolepsy and other sleep/wake disorders. TPM-1116 represents a new chemical series of OX2R agonists […]
The recent announcement by Philips regarding the discontinuation of their Alice NightOne and Alice PDx Home Sleep Testing (HST) systems has sent shockwaves through the sleep medicine community. With medical and dental practices reliant on these systems for their home sleep testing needs, the decision on which system to choose […]
Nyxoah SA has announced the DREAM U.S. pivotal study achieved a statistically significant reduction in the co-primary endpoints of 12-month AHI responder rate, per the Sher criteria, and ODI responder rate, both on an ITT basis. The DREAM study is a pivotal trial being conducted under an investigational device exemption […]
Axsome Therapeutics, Inc. has announced that AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator, achieved the primary endpoint and significantly reduced the frequency of cataplexy attacks as compared to placebo in patients with narcolepsy in the SYMPHONY Phase 3 trial. AXS-12 also reduced excessive […]
ŌURA, best known as the maker of Oura Ring, announced its recent filing with the United States International Trade Commission (ITC) against Ultrahuman, RingConn, and Circular for infringement on several patents related to the Oura Ring form factor and both internal and external components, including sensor functionality and data processing. […]
